TELA Bio, Inc. (TELA) Form 8-K — Aug 4, 2026
TELA Bio announced that CEO Antony Koblish has departed the company and resigned from the Board, effective immediately. The Board appointed Heather Getz as the new Chief Executive Officer and a Class II director, stating the transition was not the result of any disagreement. Heather Getz brings over 25 years of experience in the medical device sector, notably growing BioTelemetry before its sale to Philips. Her employment agreement includes an annual base salary of $650,000 and a target bonus opportunity of 100%.
Key figures
- Rsu granted shares
- 500000
- New ceo base salary
- 650000
- Premium options granted
- 1005000
- Standard options granted
- 1365000
- Severance months standard
- 12
- New ceo target bonus percent
- 100
- Severance months change of control
- 18
Price after filing
Close on the filing date to close N calendar days later (from $0.91). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.